Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PU.1 inhibitor (Belfer Neurodegeneration Consortium)
- Development stage
- Preclinical
- Lead developer
- Neurodegeneration Consortium
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Oral
01
Overview
PU.1 inhibitor (Belfer Neurodegeneration Consortium) is a small-molecule inhibitor of the transcription factor PU.1 (encoded by the *SPI1* gene), currently in preclinical development by the Belfer Neurodegeneration Consortium at MD Anderson Cancer Center. PU.1 is a master regulator of myeloid cell development and function, including microglia in the central nervous system. Genetic studies have identified *SPI1* as a risk locus for Alzheimer's disease, where elevated PU.1 activity drives a pro-inflammatory microglial phenotype that contributes to neurodegeneration. By selectively inhibiting PU.1, this therapeutic candidate aims to restore homeostatic microglial function and provide neuroprotection. Additionally, because PU.1 is a master regulator of hematopoiesis and is frequently dysregulated in myeloid leukemias, the inhibitor is also being explored as a potential treatment for leukemia, particularly acute myeloid leukemia (AML).
- Other names
- SPI1 inhibitorSPI-1 inhibitorSPI 1 inhibitorPU.1 small molecule inhibitorPU.1 inhibitor-Belfer Neurodegeneration Consortium (MD Anderson)-PU.1-small molecule-Alzheimer's disease-leukemia
02
Targets
SPI1 (PU.1)
Beyond the preview
Go deeper on PU.1 inhibitor (Belfer Neurodegeneration Consortium).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PU.1 inhibitor (Belfer Neurodegeneration Consortium).